Stockscreener 앱 받기
1.37
9.60%
0.12
시간 외 거래:
1.37
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com
Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN
Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN
Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®
Fate Therapeutics’ new CAR T-cell therapy fast-tracked by FDA - Investing.com South Africa
Fate Therapeutics receives RMAT designation from FDA for FT819 - TipRanks
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics gets RMAT status from FDA for lupus treatment - Seeking Alpha
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall - marketscreener.com
Fate Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus - marketscreener.com
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewswire
American Century Companies Inc. Buys 12,295 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
NK Cells Market Hits New High | Major Giants NantKwest, Fate Therapeutics, Affimed, Glycostem, Nkarta - openPR.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc. - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Position Decreased by Thrivent Financial for Lutherans - Defense World
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - MSN
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
Fate Therap stock plunges to 52-week low at $0.72 - Investing.com
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Fate Therap stock hits 52-week low at $0.87 amid sharp decline - Investing.com
FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst - The AM Reporter
Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World
Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
Q1 Earnings Estimate for Fate Therapeutics Issued By Wedbush - The AM Reporter
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance
Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World
Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World
Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register
Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks
Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks
0.92%
자본화:
|
볼륨(24시간):